38 results on '"Foley, Peter"'
Search Results
2. Paediatric indications and dosing guidance for advanced targeted treatments in Australia.
- Author
-
Mahar, Patrick D, Robertson, Susan J, Orchard, David, Baker, Christopher, and Foley, Peter
- Subjects
CHILD patients ,PEDIATRICS ,HIDRADENITIS suppurativa ,SKIN diseases ,REGULATORY approval - Abstract
As with adults, paediatric patients may benefit from a number of advanced targeted therapies for inflammatory skin disease. This brief report aims to be an accessible reference tool with respect to regulatory approval and reimbursement of these treatments within Australia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients.
- Author
-
Foley, Peter, Gebauer, Kurt, Sullivan, John, McMeniman, Erin, Shumack, Stephen, Ng, Jonathan, James, Amelia, Rawlin, Morton, Sidhu, Shireen, Tilakaratne, Dev, Turner, Murray, Radulski, Barbara, Nash, Peter, and Baker, Christopher
- Subjects
- *
PSORIASIS , *LITERATURE reviews , *PATIENT satisfaction , *ADULTS , *TREATMENT effectiveness - Abstract
Background: Over the last decade, the treatment landscape for moderate–severe psoriasis has rapidly evolved. The Australasian College of Dermatologists sought to review and update previously published treatment goals for moderate–severe psoriasis. Methods: A modified Delphi approach was used. Comprehensive literature review and guideline evaluation resulted in the development of statements and other questions to establish current clinical practices. Two rounds of anonymous voting were undertaken, with a collaborative meeting held in between to discuss areas of discordance. Overall, consensus was defined as achievement of ≥75% agreement in the range 7–9 on a 9‐point scale (1 strongly disagree; 9 strongly agree). Results: Consensus was achieved on 26/29 statements in round 1 and a further 20 statements in round 2. There was strong agreement to expanding the classification/definition of psoriasis severity by including a choice of metrics, incorporating quality of life measures, and widening the scope of high‐impact sites. Consensus was also reached on revised treatment response criteria, which were then incorporated into a new treatment algorithm. There was discordance with the current requirement to undertake a trial with established systemic agents before accessing targeted therapy. Conclusion: The ability of new targeted treatment options to change the narrative in psoriasis patient care can only be properly realised if challenges to timely and equitable access are addressed. The proposed framework for the assessment, classification and management of moderate–severe psoriasis aligns with international recommendations. Its adoption into Australian clinical practice is hoped to improve treatment outcomes and patients' satisfaction with their care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Marine Casualty Investigation, the New Australian Transport Safety Bureau
- Author
-
Foley, Peter
- Published
- 2010
5. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
- Author
-
Foley, Peter, Spelman, Lynda, Murrell, Dedee F., Mate, Eric, Tronnberg, Rebecca, and Lowe, Patricia M.
- Subjects
- *
PSORIASIS , *QUALITY of life , *HOPE - Abstract
Background: Psoriasis imposes a disease burden that can have a profound negative impact on patients' quality of life (QoL). HOPE was the first non‐interventional study conducted in patients with severe chronic plaque psoriasis in Australia that evaluated health‐related QoL in response to treatment with secukinumab. Methods: HOPE was a prospective, open‐label, single‐arm, multicentre, non‐interventional, exploratory study in patients with severe chronic plaque psoriasis in Australia. The study investigated the change in QoL, using the Dermatology Life Quality Index (DLQI), Assessment Quality of Life‐8 Dimension questionnaire (AQoL‐8D) and Psoriasis Area and Severity Index (PASI), and safety profile in response to treatment with secukinumab 300 mg SC weekly for 4 weeks followed by monthly maintenance for 58 weeks. Results: At Week 14, the mean percentage reduction in total DLQI score from baseline was −82.4% (n = 65), which indicates a substantial improvement in QoL. This level of improvement was sustained up to Week ≥58, with a mean percentage change of −87.4%. The mean percentage change from baseline for AQoL‐8D weighted total score decreased from Week 14 (41.1%) to Week 58 (35.2%), indicating an improvement in patients' QoL. A high proportion of patients achieved PASI 75/90/100 responses at Week 14 (97.0%/71.2%/34.8%), with rates sustained up to Week ≥58 (100%/87.9%/43.1%). The safety profile of secukinumab was favourable, with no cumulative or unexpected safety concerns. Conclusion: Secukinumab treatment demonstrated a striking improvement in patients' QoL in the HOPE study, the first real‐world study in patients with severe chronic plaque psoriasis in the Australian clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Treatment modalities and risk of adverse events associated with biologic therapy: A 10‐year observational review of the Australasian Psoriasis Registry.
- Author
-
Doolan, Brent J, Koye, Digsu, Ling, Joanna, Cains, Geoffrey D, Baker, Christopher, Foley, Peter, and Dolianitis, Con
- Subjects
PSORIASIS ,PSORIASIS treatment ,BIOLOGICALS ,DRUG side effects ,AUSTRALASIANS - Abstract
Background: Psoriasis is a chronic inflammatory disease affecting ~2–3% of the Australasian population. Therapeutic options include topical agents, phototherapy, systemic immunomodulators and biologic agents. Biologics present an acceptable short‐ and medium‐term safety profile, derived mainly from randomised controlled trials (RCTs) and, however, may not represent real‐world rates of adverse events (AEs). Methods: A retrospective, observational study of patients enrolled in The Australasian Psoriasis Registry from April 2008 to October 2018 was conducted. Data were collected from 104 sites in Australia and New Zealand. Patient characteristics, treatments and AE data were collected. AEs were classified by MedDRA System events. Results: 2094 patients were included (3765 patient‐treatments), comprising; 1110 phototherapy, 1280 systemic and 1375 biologic therapy patient‐treatments. Treatment arms were not mutually exclusive. The mean ± SD from date of diagnosis of psoriasis to commencement of biologic therapy was 8.9 ± 12.3 years. Methotrexate had the longest exposure time (3740.3 patient‐years), and ustekinumab had the longest median (95% CI) time on treatment, 4.3 years (2.2, 6.6). AE differences on biologic treatment were present between patients who would have been eligible or ineligible for RCTs. Approximately 29% of registry patients would have been excluded from clinical trials enrolment. Patients ineligible for RCTs had increased adjusted hazard ratios (95% CI) of: infections and infestations (2.3, 1.7–3.1; P < 0.001), cardiac (8.2, 3.5–25.6; P < 0.001), gastrointestinal (3.5, 1.52–8.0; P < 0.001), hepatobiliary (5.6 1.7–19.1; P < 0.001), psychiatric (4.7, 1.5–14.1; P = 0.006) and eye disorders (4.8 1.5–15.6; P = 0.008), compared to those eligible for RCTs. Incidence rates in the trial eligible patients were similar to those reported from RCT rates. Conclusions: This study establishes treatment modalities in use for severe psoriasis and the clinical rates of AEs associated with biologic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative.
- Author
-
Rademaker, Marius, Armour, Katherine, Baker, Christopher, Foley, Peter, Gebauer, Kurt, Gupta, Monisha, Marshman, Gillian, O'Connor, Alicia, Rubel, Diana, Sullivan, John, and Wong, Li‐Chuen
- Subjects
ECZEMA ,BOTULINUM toxin ,HYPERHIDROSIS ,DRUG therapy ,BEHAVIOR ,FOOT ,TREATMENT effectiveness - Abstract
Chronic hand/foot eczemas are common, but treatment is often challenging, with widespread dissatisfaction over current available options. Detailed history is important, particularly with regard to potential exposure to irritants and allergens. Patch testing should be regarded as a standard investigation. Individual treatment outcomes and targets, including systemic therapy, should be discussed early with patients, restoring function being the primary goal, with clearing the skin a secondary outcome. Each new treatment, where appropriate, should be considered additive or overlapping to any previous therapy. Management extends beyond mere pharmacological or physical treatment, and requires an encompassing approach including removal or avoidance of causative factors, behavioural changes and social support. To date, there is little evidence to guide sequences or combinations of therapies. Moderately symptomatic patients (e.g. DLQI ≥ 10) should be started on a potent/super‐potent topical corticosteroid applied once or twice per day for 4 weeks, with tapering to twice weekly application. If response is inadequate, consider phototherapy, and then a 12‐week trial of a retinoid (alitretinoin or acitretin). Second line systemic treatments include methotrexate, ciclosporin and azathioprine. For patients presenting with severe symptomatic disease (DLQI ≥ 15), consider predniso(lo)ne 0.5–1.0 mg/kg/day (or ciclosporin 3 – 5 mg/kg/day) for 4–6 weeks with tapering, and then treating as for moderate disease as above. In non‐responders, botulinum toxin and/or iontophoresis, if associated with hyperhidrosis, may sometimes help. Some patients only respond to long‐term systemic corticosteroids. The data on sequencing of newer agents, such as dupilumab or JAK inhibitors, are immature. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Atopic dermatitis in adults: An Australian management consensus.
- Author
-
Smith, Saxon, Baker, Christopher, Gebauer, Kurt, Rubel, Diana, Frankum, Brad, Soyer, H. Peter, Weightman, Warren, Sladden, Michael, Rawlin, Morton, Headley, Alexander P., Somerville, Colin, Beuth, Julie, Logan, Nick, Mewton, Erin, and Foley, Peter
- Subjects
DERMATOLOGISTS ,ATOPIC dermatitis ,QUALITY of life ,ADULTS - Abstract
Background/Objectives: Atopic dermatitis (AD) has significant negative impact on health‐related quality of life, mood, sleep, work productivity and everyday activities. Research into the use of new drugs in the management of AD continues to develop, and international updates and recommendations have been published. However, questions remain in the Australian setting. This consensus aims to provide evidence‐based insights and practical advice on the management of adult AD in Australia. Methods: A panel (five dermatologists and one clinical immunologist) met to review the literature, critically examine clinical questions of relevance to Australian healthcare practitioners and develop a series of recommendation statements. A consensus panel, comprising the initial panel plus nine additional members, used a 2‐round Delphi voting process to determine a set of final guidance statements. Consensus: ≥75% agreement in the range 7–9. Results: Round 1 voting comprised 66 guidance statements. Of these, consensus was reached on 26, which were retained, and five were removed. The remainder (35) were modified and one new guidance statement was added for inclusion in round 2 voting. After round 2, consensus was reached on 35, which were retained, and one was removed (considered redundant). The 61 guidance statements upon which consensus was reached were then used to support a series of core consensus recommendations and a management flow chart. Conclusions: Expert consensus recommendations providing practical guidance of clinical relevance to specialists and primary care physicians in Australia have been developed. Dissemination of this guidance and evaluation of its impact on patient outcomes remain to be undertaken. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Initial assessment of the early arthritis for psoriatic patients diagnostic questionnaire in dermatology clinics in Australia, Korea and China.
- Author
-
Jo, Seong‐Jin, Foley, Peter, Oakley, Stephen Philip, Zhang, Jianzhong, Zheng, Min, Shin, Kichul, McGonagle, Dennis, Gisondi, Paolo, Tinazzi, Ilaria, Butcher, Belinda E., and Handel, Malcolm
- Subjects
- *
PSORIATIC arthritis , *CRONBACH'S alpha , *INTRACLASS correlation , *STATISTICAL reliability , *DERMATOLOGY , *CLINICS - Abstract
Objectives: To conduct initial assessment of the early arthritis for psoriatic patients (EARP) questionnaire for Australian, Korean and Chinese populations using translated and linguistically validated versions. To measure the proportion of patients with psoriatic arthritis (PsA) among patients with psoriasis who attended dermatology clinics. Methods: Questionnaires were translated and culturally validated into Australian English, Korean and Chinese. A multicenter, observational, descriptive estimate of the proportion of patients with PsA among patients with psoriasis attending dermatology clinics in Australia, Korea and China was conducted. Initial assessments included evaluations of floor and ceiling effects, internal consistency (using Cronbach's alpha), test‐retest reliability (using intraclass coefficient), and correlations between EARP score and rheumatology findings. If the initial EARP score was ≥3, patients were assessed by a rheumatologist for PsA within 3 months of their retest questionnaire. Results: Two hundred and fifty patients participated. Translated EARP questionnaires showed satisfactory internal consistency and test‐retest reliability. A potential floor effect was observed for the Chinese and Korean versions. Cronbach's alpha was 0.885 (Australian), 0.776 (Korean) and 0.789 (Chinese), indicating acceptable internal consistency. Intraclass correlation coefficients were 0.89 (Australian), 0.86 (Korean) and 0.87 (Chinese), indicating acceptable test‐retest reliability. EARP summary scores had weak to moderate linear correlation with the relevant PsA assessments. Overall, 32 (12.8%) patients were diagnosed with PsA based on Classification for Psoriatic Arthritis (CASPAR) score. Conclusion: The Australian, Korean, and Chinese versions of the EARP questionnaire are suitable for the early detection of PsA symptoms in patients with psoriasis by dermatologists working in specialist dermatology clinics. Trial registration: NCT02470481. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia.
- Author
-
See, Jo ‐ Ann, Shumack, Stephen, Murrell, Dedee F, Rubel, Diana M, Fernández ‐ Peñas, Pablo, Salmon, Robert, Hewitt, Daniel, Foley, Peter, and Spelman, Lynda
- Subjects
DISEASE prevalence ,EPIDEMIOLOGY ,ACTINIC keratosis ,SQUAMOUS cell carcinoma ,DISEASE progression ,PHOTODYNAMIC therapy - Abstract
Australia has the highest prevalence of actinic keratoses ( AK) worldwide. Because of the risk of transformation of AK to invasive squamous cell carcinomas, consensus guidelines recommend that AK are removed using appropriate therapies to prevent progression to invasive disease. Daylight photodynamic therapy ( PDT) is emerging as an efficacious treatment for AK, particularly for patients who require treatment of large areas of chronic actinic damage that can be exposed easily to daylight. Daylight PDT with methyl aminolevulinate ( MAL) cream is a simple treatment for AK, almost painless, well tolerated and convenient, requiring minimal time in the clinic. Randomised controlled studies from northern Europe and Australia support the use of daylight PDT as an effective therapy for grade I and II AK on the face and scalp. There is sufficient daylight to conduct daylight PDT in Australia at any time of the year and during most weather conditions. Hence, daylight PDT with MAL can be included as an effective and well-tolerated new treatment option for the treatment of AK in Australia. These consensus recommendations provide guidelines for Australian clinicians on the use of daylight PDT in the treatment of diagnosed AK. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program.
- Author
-
Foley, Peter, Freeman, Michael, Gebauer, Kurt, Murrell, Dedee, Shumack, Stephen, Tyson, Christopher, and Varigos, George
- Subjects
- *
EFALIZUMAB , *PSORIASIS treatment , *SKIN diseases , *DRUG efficacy , *THERAPEUTICS , *PATIENTS - Abstract
Background Psoriasis is a chronic skin disease that can impact heavily on a patient’s well-being. Efalizumab, a unique, targeted, biological therapy, has demonstrated efficacy in treating moderate-to-severe, chronic plaque psoriasis with ≤36 months of continuous therapy. The objective of this Extended Access Program (EAP) was to evaluate further the benefit of efalizumab as long-term therapy in a real-world clinical setting. Methods After an initial conditioning dose of efalizumab (0.7 mg/kg subcutaneously), a weekly dose of efalizumab (1.0 mg/kg) was administered for ≤21 months. Patients with reduced Psoriasis Area and Severity Index (PASI) scores (≥50%, or a score ≤8) at month 3 entered the long-term maintenance treatment period. Results In total, 101 patients (>18 years) with severe plaque psoriasis enrolled on the EAP, of these 93 (92.1%) met all the inclusion criteria. After 3 months of treatment, 84/101 (83.2%) patients had evaluable data and entered the maintenance period. After 3 months, 57/84 (67.9%) patients had achieved PASI-50. Using an intent-to-treat analysis, after 21 months of treatment, PASI-75 and PASI-50 were achieved by 43/101 (42.6%) and 69/101 (68.3%) of patients, respectively. Efalizumab was generally well tolerated during the 21 months of continuous therapy. Conclusion Efalizumab, 1.0 mg/kg/week, is effective and well tolerated in a ‘real world’ clinical setting, providing enduring reduction of psoriasis symptoms for up to 21 months. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
12. Solar keratosis: Epidemiology, pathogenesis, presentation and treatment.
- Author
-
Holmes, Cara, Foley, Peter, Freeman, Michael, and Chong, Alvin H.
- Subjects
- *
KERATOSIS , *ULTRAVIOLET radiation , *SKIN diseases , *IMMUNOSUPPRESSION , *PAPILLOMAVIRUSES , *SUNSCREENS (Cosmetics) - Abstract
Solar keratosis is a common problem encountered by dermatologists, particularly in Australia. Solar keratosis is most commonly found on sun-exposed areas such as the scalp, face and forearms. UV radiation is thought to be the major aetiological factor, with age, immunosuppression and human papillomavirus being important contributing factors. Solar keratosis usually presents as a discrete, variably erythematous and irregular lesion with a scaly surface. Although the exact rate of malignant transformation to squamous cell carcinoma is unknown, the majority of squamous cell carcinomas appear to arise from within solar keratosis. For this reason, solar keratosis is commonly treated and, consequently, an increasing number of therapeutic options is now available. Traditional therapies, such as liquid nitrogen cryotherapy, are still popular, but newer choices, such as photodynamic therapy and imiquimod cream, are now providing further options with similar efficacy and superior adverse effect profiles, albeit at a higher cost. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.
- Author
-
Braathen, Lasse R., Szeimies, Rolf-Markus, Basset-Seguin, Nicole, Bissonnette, Robert, Foley, Peter, Pariser, David, Roelandts, Rik, Wennberg, Ann-Marie, Morton, Colin A., and International Society for Photodynamic Therapy in Dermatology
- Subjects
PHOTOCHEMOTHERAPY ,SKIN cancer ,CANCER treatment ,BASAL cell carcinoma ,THERAPEUTIC use of amino acids ,AMINO acids ,BASAL cell nevus syndrome ,CLINICAL trials ,COMPARATIVE studies ,KERATOSIS ,RESEARCH methodology ,MEDICAL cooperation ,PATIENT satisfaction ,PHOTOSENSITIVITY disorders ,RESEARCH ,SKIN diseases ,SKIN tumors ,SQUAMOUS cell carcinoma ,EVALUATION research ,DISEASE incidence ,BLIND experiment ,IMMUNOCOMPROMISED patients ,BOWEN'S disease ,PREVENTION - Abstract
Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen''s disease, and basal cell carcinoma (superficial and nodular). This article presents up-to-date, practical, evidence-based recommendations on the use of topical PDT using 5-aminolevulinic acid or methyl aminolevulinate for the treatment (and prevention) of nonmelanoma skin cancers. A systematic literature review was conducted (using MEDLINE), and recommendations were made on the basis of the quality of evidence for efficacy, safety/tolerability, cosmetic outcome, and patient satisfaction/preference. Topical PDT is highly effective in the treatment of actinic keratoses, Bowen''s disease, superficial and thin nodular basal cell carcinomas, with cosmesis typically superior to that achieved with existing standard therapies. PDT may also be a means of preventing certain nonmelanoma skin cancers in immunosuppressed patients. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
14. RESEARCH REPORT Chronic actinic dermatitis: A retrospective analysis of 44 cases referred to an Australian photobiology clinic.
- Author
-
Yap, Lee Mei, Foley, Peter, Crouch, Rohan, and Baker, Christopher
- Subjects
- *
PHOTOBIOLOGY , *SKIN disease diagnosis , *ACTIN , *ERYTHEMA , *DERMATOLOGY - Abstract
A retrospective study was performed to analyse the clinical and photobiological features and therapeutic outcomes of 44 patients with chronic actinic dermatitis who were evaluated over an 8.3-year period. The study population comprised 37 men and seven women with a mean age of 62.7 years (range 26–85 years). The most common abnormal phototest results were decreased minimal erythema doses to both UVA and -B (73.8%), and to UVA alone (14.3%). Twenty-six patients (78.8%) had at least one allergic, photoallergic or combined allergic/photoallergic reaction. A total of 139 positive contact or photocontact reactions were recorded (mean 4.2 per patient). Most commonly, treatment consisted of photoprotection, topical corticosteroids and episodic use of systemic agents, in particular azathioprine. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
15. The Frequency of Common Skin Conditions in Preschool-aged Children in Australia: Seborrheic Dermatitis and Pityriasis Capitis (Cradle Cap).
- Author
-
Foley, Peter, Zuo, Yeqin, Plunkett, Anne, Merlin, Kate, and Marks, Robin
- Subjects
SKIN inflammation ,PRESCHOOL children - Abstract
Objective: To determine the prevalence and severity of seborrheic dermatitis and pityriasis capitis in Australian preschool-aged children. Design: A stratified cross-sectional skin survey using cluster sampling of centers throughout Victoria, Australia. Setting: The study population included children attending child care centers, preschools, and Maternal and Child Health Centers, with the reference population being Australian children 5 years and younger. Participants: Of the 1634 children in the original sample, 1116 children aged 11 days to 5 years 11 months were included in the study. Intervention: Parents completed a questionnaire recording demographic information and personal and family history of skin problems and related diseases. A dermatologist performed a total skin examination, including the diaper area for children younger than 12 months. Main Outcome Measure: The age- and sex-specific prevalence rates and site and severity of seborrheic dermatitis and pityriasis capitis were measured. Results: The overall age- and sex-adjusted prevalence of seborrheic dermatitis was 10.0% (95% confidence interval [CI], 8.2%-11.7%): 10.4% (95% CI, 7.8%-12.9%) in boys and 9.5% (95% CI, 7.0%-12.0%) in girls. This was highest in the first 3 months of life, decreasing rapidly by the age of 1 year, after which it slowly decreased over the next 4 years. Most (71.9%) had disease classified as minimal to mild. Pityriasis capitis occurred in 41.7% (95% CI, 38.8%-44.6%) of the 1116 children examined, with 85.8% categorized as minimal to mild only. Conclusions: Seborrheic dermatitis and pityriasis capitis are common in early childhood. Most children have minimal to mild disease that would require little if any treatment. Education programs directed at those caring for preschool-aged children are needed to provide information on simple preventative measures and treatment, if necessary, that could easily reduce the morbidity associated with these very common conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
16. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen® ) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.
- Author
-
Freeman, Susanne, Howard, Anne, Foley, Peter, Rosen, Robert, Wood, Glenda, See, Jo-Ann, and Gray, Susan
- Subjects
ADRENOCORTICAL hormones ,ATOPIC dermatitis - Abstract
SUMMARY The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty-one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double-blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events (rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short-term use of desonide 0.05% lotion as a suitable agent for the short-term treatment of facial dermatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
17. Incidence of non-melanocytic skin cancer treated in Australia.
- Author
-
Giles, Graham G., Marks, Robin, and Foley, Peter
- Subjects
SKIN cancer diagnosis ,HUMAN sexuality ,HEALTH - Abstract
Determines the incidence of skin cancer treated in Australia. Standardized rates for basal cell carcinoma and squamous cell carcinoma; Effects of age, sex, occupation, residence and country on the development of the disease; Increase in the incidence of non-melanocytic cancer in men than in women.
- Published
- 1988
- Full Text
- View/download PDF
18. Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis.
- Author
-
Foley, Peter
- Subjects
- *
PHOTOCHEMOTHERAPY , *THERAPEUTICS , *BASAL cell carcinoma , *KERATOSIS , *SKIN diseases - Abstract
The article focuses on the clinical efficacy of methyl aminolaevulinate (MAL) photodynamic therapy (PDT) in basal cell carcinoma (BCC) and solar keratosis. Two studies in Australia and the U.S. have compared nodular BCC complete response rates with MAL PDT and placebo PDT. In the Australian study, as tumour depth increased efficacy diminished; in the U.S. where debulking was somewhat more aggressive, no loss of efficacy with increasing depth was observed. However, this finding does suggest that the procedure may be best used for thin nodular BCC.
- Published
- 2005
- Full Text
- View/download PDF
19. A decade of Australian methotrexate dosing errors.
- Author
-
Gupta, Monisha, Rademaker, Marius, Sullivan, John R., and Foley, Peter
- Subjects
METHOTREXATE ,AMINOBENZOIC acids ,MEDICATION errors - Abstract
A letter to the editor in response to the article "A decade of Australian methotrexate," that was published in a previous issue of the journal is presented.
- Published
- 2016
- Full Text
- View/download PDF
20. Legal considerations of consent and privacy in the context of clinical photography in Australian medical practice.
- Author
-
Mahar, Patrick D., Foley, Peter A., Sheed-Finck, Alexander, and Baker, Christopher S.
- Subjects
MEDICAL photography ,MEDICAL record access control ,MEDICAL records ,PRIVACY ,SECURITY systems - Abstract
The article discusses the integral aspects of clinical photography with regards to consent and privacy in Australian Medical practice. It states that the clinical photography, being to medical practice, becomes a part of patient’s medical record and must be kept in storage for several years. It also reveals that the photographs must be taken with the informed consent of the patient and can be accessed by the patient according to the freedom of information legislation.
- Published
- 2013
- Full Text
- View/download PDF
21. Practical aspects of methyl aminolaevulinate photodynamic therapy.
- Author
-
Foley, Peter
- Subjects
- *
PHOTOCHEMOTHERAPY , *KERATOSIS , *BASAL cell carcinoma treatment , *OINTMENTS , *PORPHYRINS , *THERAPEUTICS - Abstract
The article focuses on the use of methyl aminolaevulinate (MAL) photodynamic therapy (PDT), approved by the Therapeutic Goods Administration in Australia for treating non-pigmented and non-hyperkeratotic solar keratoses on the face and scalp and basal cell carcinoma (BCC). It mentions the application of Metvix® cream for three hours under occlusion as the initial step of the therapy which is made up of 16% MAL. It adds that photoactive porphyrins accumulate only where MAL is applied.
- Published
- 2005
- Full Text
- View/download PDF
22. Are solar keratoses more common on the driver's side?
- Author
-
Foley, Peter, Lanzer, Daniel, and Marks, Robin
- Subjects
- *
KERATOSIS , *AUTOMOBILE drivers , *SUNSHINE , *HEALTH - Abstract
Investigates the commonality of solar keratoses on the driver's side of people in Australia. Exposure of drivers on sunlight; Amount of sunlight to cause solar keratoses; Prevalence of the skin problem in the population; Potential hazards of sunlight.
- Published
- 1986
- Full Text
- View/download PDF
23. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.
- Author
-
Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF, Su CS, and Katelaris CH
- Subjects
- Humans, Australia, Severity of Illness Index, Treatment Outcome, Dermatitis, Atopic complications, Eye Diseases chemically induced, Eye Diseases drug therapy
- Abstract
Background/objectives: Dupilumab-associated ocular surface disease (DAOSD) is of particular relevance in patients with atopic dermatitis (AD). Guidance on DAOSD assessment and management in the Australian setting is needed to reduce its impact and minimise disruption to treatment., Methods: A systematic review of the literature was undertaken to identify data pertaining to the incidence, pathophysiology, risk factors and management of DAOSD. A critical review of this literature was used to inform a decision framework for dupilumab-prescribers and develop a graded severity scoring tool to guide appropriate management options., Results: DAOSD typically emerges within 4 months of commencing dupilumab and the occurrence of new events diminishes over time. The reported incidence varies widely depending on the nature and source of the data: 8.6-22.1% (clinical trials programme), 0.5-70% (real-world data; differences in study size, duration of follow-up, ophthalmologist intervention, use of prophylaxis). Occurrence increases with AD severity and in patients with prior history of ocular disease; pathophysiology is still to be fully characterised. Management options have evolved over time and include lubricants/artificial tears, corticosteroids, calcineurin inhibitors, antihistamines, anti-inflammatory agents and antimicrobial agents. Current therapies aim to resolve symptoms or reduce severity to levels sufficiently tolerable to enable continuation of dupilumab therapy., Conclusions: Recommendations for DAOSD assessment and management include identification of high-risk patients, vigilance for red flags (keratoconus, herpetic and bacterial keratitis), regular assessment of symptom severity (before and during dupilumab therapy), conservative management of mild DAOSD by the prescribing physician and ophthalmologist referral for collaborative care of moderate-severe DAOSD and high-risk patients., (© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists.)
- Published
- 2022
- Full Text
- View/download PDF
24. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
- Author
-
Foley P, Manuelpillai N, Dolianitis C, Cains GD, Mate E, Tronnberg R, and Baker C
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized, Australia, Humans, Quality of Life, Severity of Illness Index, Treatment Outcome, Biological Products therapeutic use, Psoriasis drug therapy
- Abstract
Background: Drug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long-term effectiveness, safety, and real-world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaque psoriasis (CPP) in the Australian clinical setting., Methods: Data of all patients (aged ≥18 years) from Australasian Psoriasis Registry (APR) treated with secukinumab were analysed. The primary objective was to describe the drug survival of secukinumab at 9 months. Key secondary objectives included drug survival of secukinumab at 3, 6, 15, and 21 months, stratified by biologic-naïve vs biologic-experienced patients; proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75/90/100 responses; and changes in health-related quality of life over time utilising the Dermatology Life Quality Index (DLQI)., Results: Of 294 patients included in this analysis, 110 (37.4%) were biologic-naïve and 184 (62.6%) biologic-experienced. Kaplan-Meїer drug survival rates in biologic-naïve vs biologic-experienced patients were 0.92 vs. 0.86 (9 months) and 0.82 vs. 0.68 (21 months), respectively. The proportion of patients with PASI 75/90/100 responses for biologic-naïve vs. biologic-experienced was 100/87.7/38.4 vs 98.5/61.5/27.2 (9 months) and 100/81.0/41.7 vs. 98.4/62.0/24.2 (21 months), respectively. The mean (standard deviation [SD]) DLQI in biologic-naïve vs. experienced patients was 2.2 (4.1) vs. 3.1 (5.2) (9 months) and 1.4 (2.5) vs. 3.1 (5.3) (21 months). No new safety signals were observed., Conclusions: Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real-world setting, in biologic-naïve and biologic-experienced patients with severe CPP., (© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists.)
- Published
- 2022
- Full Text
- View/download PDF
25. Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital.
- Author
-
Ringin S, Baker CS, Foley P, and Daniel BS
- Subjects
- Acitretin adverse effects, Adult, Australia, Child, Humans, Retrospective Studies, Tertiary Care Centers, Pityriasis Rubra Pilaris diagnosis, Pityriasis Rubra Pilaris drug therapy, Pityriasis Rubra Pilaris pathology
- Abstract
Pityriasis rubra pilaris (PRP) is a group of uncommon chronic inflammatory skin conditions with unclear pathophysiology and etiology. To date there is limited published literature and no clinical guidelines for the management of PRP. Infliximab, alone or in combination, is the most widely published successful treatment for adults and etanercept for pediatric populations. We present a case series of patients diagnosed with PRP. Retrospective data were collected from a tertiary Australian dermatology department between January 2010 and December 2019 on patients with PRP. Electronic medical records and pathology database were searched. A total of 13 patients were included. Twelve of the 13 patients used topical agents and three patients attempted narrow-band ultraviolet B phototherapy. All patients received acitretin as first line systemic agent with the dose varying from 10 to 50 mg daily. Six patients treated with acitretin reported adverse events, requiring dose reduction or cessation. Of the nine patients who did not receive a biologic agent, complete clearance of PRP was achieved in five cases. At least one biologic agent was used in four cases with two experiencing a marked improvement. Overall, complete clearance was achieved in six patients. PRP continues to be a challenge to treat with many treatment options used with variable efficacy., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
26. Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry.
- Author
-
Berry W, Daniel BS, Baker C, and Foley P
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Australia, Cyclosporine adverse effects, Dermatologic Agents adverse effects, Female, Headache chemically induced, Humans, Hypertension chemically induced, Male, Middle Aged, Nausea chemically induced, Registries, Renal Insufficiency chemically induced, Severity of Illness Index, Time Factors, Treatment Outcome, Young Adult, Cyclosporine therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Published
- 2020
- Full Text
- View/download PDF
27. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.
- Author
-
Wang C, Rademaker M, Baker C, and Foley P
- Subjects
- Anti-Infective Agents therapeutic use, Australia, COVID-19, Coronavirus Infections complications, Humans, New Zealand, Pandemics, Pneumonia, Viral complications, SARS-CoV-2, Skin Diseases complications, Betacoronavirus, Biological Factors therapeutic use, Coronavirus Infections therapy, Immunosuppressive Agents therapeutic use, Pneumonia, Viral therapy, Skin Diseases drug therapy
- Abstract
Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population during the COVID-19 pandemic. There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID-19 disease or more likely to have severe disease. As such, clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. In patients with suspected or confirmed COVID-19 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should be continued. In all patients, and their immediate close contacts, the importance of preventative measures to minimise human-to-human transmission cannot be overemphasised., (© 2020 The Australasian College of Dermatologists.)
- Published
- 2020
- Full Text
- View/download PDF
28. Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative.
- Author
-
Rademaker M, Agnew K, Andrews M, Baker C, Foley P, Gebauer K, Gupta M, Rubel DM, Somerville C, Sullivan J, and Wong LC
- Subjects
- Adolescent, Adult, Anti-Bacterial Agents therapeutic use, Australia, Dermatologic Agents therapeutic use, Humans, Immunosuppressive Agents therapeutic use, New Zealand, Young Adult, Dermatitis, Atopic drug therapy
- Abstract
With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success., (© 2019 The Australasian College of Dermatologists.)
- Published
- 2020
- Full Text
- View/download PDF
29. Solar urticaria - An Australian case series of 83 patients.
- Author
-
Photiou L, Foley P, and Ross G
- Subjects
- Adolescent, Adult, Aged, Australia, Child, Female, Histamine Antagonists therapeutic use, Humans, Male, Middle Aged, Pruritus etiology, Retrospective Studies, Sunscreening Agents therapeutic use, Urticaria therapy, Young Adult, Sunlight adverse effects, Ultraviolet Rays adverse effects, Urticaria etiology
- Abstract
Solar urticaria (SU) is a rare form of urticaria with a pathogenesis that is poorly understood. It affects all skin types, can be difficult to diagnose, and is challenging to manage effectively. We conducted a retrospective review of patients with SU in our institution. A total of 83 patients (56 females) were identified as having SU. The mean age was 32 years (7-74) at first development of symptoms/signs of SU. Pruritus was the most common symptom reported (79%). Of the 60 patients who underwent monochromator testing at least once, 35 had SU confirmed with most reacting to visible light and UVA, or to UVA alone. Antihistamines and sun avoidance remain the mainstay treatment for SU but other treatments, including omalizumab, are of potential interest in treating patients with recalcitrant SU. The characterisation of this large case series of patients may help dermatologists recognise and manage this rare disorder appropriately., (© 2018 The Australasian College of Dermatologists.)
- Published
- 2019
- Full Text
- View/download PDF
30. Psoriasis and cancer. An Australian/New Zealand narrative.
- Author
-
Rademaker M, Rubel DM, Agnew K, Andrews M, Armour KS, Baker C, Foley P, Gebauer K, Goh MS, Gupta M, Marshman G, Prince HM, and Sullivan J
- Subjects
- Australia epidemiology, Biological Products therapeutic use, Humans, New Zealand epidemiology, Risk Factors, Immunologic Factors therapeutic use, Neoplasms epidemiology, PUVA Therapy, Psoriasis drug therapy
- Abstract
Patients with psoriasis have an increased risk of cancer, which may be due to impaired immune surveillance, immune modulatory treatments, chronic inflammation and/or co-risk factors such as obesity. The increase in treatment-independent solid cancers, including urinary/bladder cancers, oropharynx/larynx, liver/gallbladder and colon/rectal cancers, seem to be linked to alcohol and smoking. Lung cancer and nonmelanoma skin cancer are also increased in patients with psoriasis. The risk of nonmelanoma skin cancer increases with age and severity of psoriasis. It is also higher in men, particularly for squamous cell carcinoma, which may reflect previous exposure to PUVA and/or ciclosporin. The risk of cutaneous T-cell lymphoma is substantially higher in patients with moderate-to-severe psoriasis. Biologic therapies are independently associated with a slight increase risk of cancer, but this is less than ciclosporin, with the risk confounded by disease severity and other co-risk factors. The risk of cancer from low-dose methotrexate is likely minimal. In contrast, acitretin is likely protective against a variety of solid and haematological malignancies. The data on small molecule therapies such as apremilast are too immature for comment, although no signal has yet been identified. The decision whether to stop psoriasis immune modulatory treatments following a diagnosis of cancer, and when to resume, needs to be considered in the context of the patients' specific cancer. However, there is no absolute need to stop any treatment other than possibly ciclosporin, unless there is a concern over an increased risk of serious infection or drug-drug interaction with cancer-directed therapies, including radiotherapy., (© 2018 The Australasian College of Dermatologists.)
- Published
- 2019
- Full Text
- View/download PDF
31. Treatment goals for moderate to severe psoriasis: an Australian consensus.
- Author
-
Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, Soyer HP, Wu J, Chan J, Nash P, Rawlin M, Radulski B, and Foley P
- Subjects
- Australia, Humans, Severity of Illness Index, Patient Care Planning, Psoriasis drug therapy
- Abstract
Background/objectives: The high incidence of comorbidities in patients with psoriasis, significant impact on quality of life and patients' dissatisfaction with treatment led a European group to develop a consensus position on psoriasis treatment goals. There is an evident need for similar treatment goals in Australia. The aim of this project was to develop Australian treatment goals that reflect the local environment., Methods: A panel of 12 representatives was drawn from across Australia consisting of nine dermatologists and a rheumatologist, a dermatology nurse and a general practitioner (GP)/dermatology trainee. The group met on three occasions between September 2011 and March 2012. The panel undertook a literature review and critically examined available evidence-based treatment goals. A questionnaire relating to psoriasis assessment and specific treatment outcomes was developed. Following discussion and debate, recommended treatment goals for psoriasis patients in Australia were determined., Results: The panel agreed by consensus on recommended psoriasis treatment goals in the Australian environment. There was recognition that in addition to psoriasis area severity index (PASI) assessment, a quality of life assessment was highly relevant in determining psoriasis severity and treatment outcome. Mild psoriasis was defined as PASI ≤ 10 and a dermatology life quality index (DLQI) ≤ 10, with moderate to severe psoriasis defined as PASI > 10 and/or DLQI > 10. The presence of certain definedclinical features would elevate a patient's classification from mild to moderate/severe. The target for treatment was defined as a maintained change in PASI ≥ 75% improvement and DLQI ≤ 5. These largely concurred with the European treatment goals. A flow chart for psoriasis management in Australia based on outcome measures was developed., Conclusions: There is a need to identify and articulate treatment goals for psoriasis. Assessment of psoriasis severity requires both physical scoring (PASI) and consideration of quality of life measures (DLQI). Identification of treatment goals will guide clinicians in treatment decision-making, enhance the availability and appropriate use of therapies and increase patient satisfaction with their care., (© 2013 The Authors. Australasian Journal of Dermatology © 2013 The Australasian College of Dermatologists.)
- Published
- 2013
- Full Text
- View/download PDF
32. Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis.
- Author
-
Baker CS, Foley PA, and Braue A
- Subjects
- Administration, Cutaneous, Adolescent, Adult, Aged, Australia, Cohort Studies, Cross-Sectional Studies, Dermatologic Agents administration & dosage, Early Diagnosis, Female, Health Status, Humans, Male, Middle Aged, Psoriasis diagnosis, Psoriasis drug therapy, Risk Factors, Severity of Illness Index, Sickness Impact Profile, Surveys and Questionnaires, Psoriasis psychology, Quality of Life
- Abstract
Background/objectives: Internationally, the understanding of psoriasis has advanced in recent years to the point now where it is no longer considered a benign or cosmetic skin condition but a systemic, immune-mediated disease associated with significant comorbidities and considerable detriment to quality of life. The aim of this study was to gain a better understanding of the physical, psychosocial and medical burden of psoriasis on Australian adults and the impact on health status., Methods: Two large-scale multi-centre cross-sectional studies of Australian adults with psoriasis were conducted during 2010 and 2011, with the participation of a national patient representative group (Psoriasis Australia). The studies were based on detailed questionnaires that were self-completed by individuals with psoriasis., Results: A total of 362 and 330 completed surveys were received in 2010 and 2011, respectively. A significant physical, psychosocial and medical burden was reported by the respondents. It was noteworthy that patients reported actively concealing their disease from the general public (83%), work colleagues (65%), friends (58%), employers (49%), family (40%), close friends (39%) and spouse/partner (20%). The mean five-dimension European quality of life (EQ-5D) score for the 2011 cohort was 0.73, representing a significant impact on their HRQoL. The presence of comorbidities, found in three-quarters of the cohort, was associated with an even greater detriment to their HRQoL (mean score 0.64)., Conclusions: Psoriasis imposes a significant psychosocial burden on the lives of patients, including a profound impact upon their personal and professional relationships, social interactions and quality of life, to a degree comparable to other serious chronic conditions. This study highlights the importance of collaboration between primary and specialist health-care providers in developing patient management strategies that address the spectrum of physical and psychological manifestations associated with psoriasis., (© 2013 AbbVie Pty Ltd Australasian Journal of Dermatology © 2013 The Australasian College of Dermatologists.)
- Published
- 2013
- Full Text
- View/download PDF
33. Actinic prurigo.
- Author
-
Ross G, Foley P, and Baker C
- Subjects
- Adolescent, Adult, Australia, Child, Child, Preschool, Female, Humans, Male, Photosensitivity Disorders metabolism, Prurigo metabolism, Photosensitivity Disorders pathology, Photosensitivity Disorders therapy, Prurigo pathology, Prurigo therapy
- Abstract
Actinic Prurigo (AP), an uncommon idiopathic photodermatosis, presents a distinct clinical picture and can be severely debilitating. The clinical features, investigation and treatment of AP are reviewed. We report the experience of an Australian photobiology unit with this condition.
- Published
- 2008
- Full Text
- View/download PDF
34. Vitamin D and adult bone health in Australia and New Zealand: a position statement.
- Author
-
Chia AL, Shumack S, and Foley P
- Subjects
- Adult, Australia, Humans, New Zealand, Practice Guidelines as Topic, Sunlight, Vitamin D physiology, Bone Diseases etiology, Bone Diseases prevention & control, Vitamin D Deficiency complications, Vitamin D Deficiency prevention & control
- Published
- 2005
- Full Text
- View/download PDF
35. A prospective study of the use of cryosurgery for the treatment of actinic keratoses.
- Author
-
Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, Murrell D, Anderson C, Weightman W, Reid C, Watson A, and Foley P
- Subjects
- Adult, Aged, Aged, 80 and over, Australia, Cryosurgery, Face, Female, Humans, Keratosis pathology, Male, Middle Aged, Prospective Studies, Scalp, Skin Neoplasms pathology, Treatment Outcome, Keratosis surgery, Skin Neoplasms surgery
- Abstract
Background: Actinic keratoses are the most common actinic lesions on Caucasian skin. Cryosurgery with liquid nitrogen is commonly used to treat actinic keratoses, but there have been few studies examining the true rate of cure in everyday dermatologic practice., Aim: To determine prospectively the true efficacy of cryosurgery as a treatment for actinic keratoses in everyday dermatologic practice., Methods: A prospective, multicentered study (a subsidiary study of a photodynamic therapy trial) was performed. Patients with untreated actinic keratoses greater than 5 mm in diameter on the face and scalp were recruited. Eligible lesions received a single freeze-thaw cycle with liquid nitrogen given via a spray device and were reviewed 3 months thereafter. Each center used their preferred freeze time. The only treatment criterion was complete freezing of actinic keratoses and a 1-mm rim of normal skin. Treated lesions were assessed as complete response or noncomplete response. The influence of the duration of freeze, cosmetic outcomes, and adverse events were examined., Results: Ninety adult patients from the community with 421 eligible actinic keratoses were recruited. The overall individual complete response rate was 67.2%[SEM = +/-3.5%; 95% confidence interval (CI) = 60.4-74.1%]. Complete response was 39% for freeze times of less than 5 s, 69% for freeze times greater than 5 s, and 83% for freeze times greater than 20 s. Cosmetic outcomes were good to excellent in 94% of complete response lesions. The main adverse events were pain, stinging, and burning during treatment, and hypopigmentation after healing., Conclusions: Cryosurgery is an effective treatment for actinic keratoses. The true complete response rate is significantly lower than that previously reported. The freeze duration influences successful treatment. Adverse events are mild and well tolerated.
- Published
- 2004
- Full Text
- View/download PDF
36. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.
- Author
-
Freeman S, Howard A, Foley P, Rosen R, Wood G, See JA, and Gray S
- Subjects
- Administration, Topical, Adolescent, Adult, Anti-Inflammatory Agents adverse effects, Australia, Dermatitis, Atopic diagnosis, Dermatitis, Seborrheic diagnosis, Desonide adverse effects, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Emulsions, Esthetics, Facial Dermatoses diagnosis, Facial Dermatoses drug therapy, Female, Follow-Up Studies, Glucocorticoids, Humans, Male, Middle Aged, Probability, Reference Values, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Dermatitis, Atopic drug therapy, Dermatitis, Seborrheic drug therapy, Desonide therapeutic use
- Abstract
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis. Eighty-one adult patients were randomized to receive desonide 0.05% lotion or its vehicle, applied twice daily for 3 weeks under double-blind conditions. In the active treatment group, 88% of patients had their skin condition cleared or almost cleared and only two patients experienced cutaneous adverse events (rash and pruritus). The acceptability of the lotion was high; 95% of patients stated they would use this topical corticosteroid again. These data support the short-term use of desonide 0.05% lotion as a suitable agent for the short-term treatment of facial dermatitis.
- Published
- 2002
- Full Text
- View/download PDF
37. The results of photopatch testing 172 patients to sunscreening agents at the photobiology clinic, St Vincent's Hospital, Melbourne.
- Author
-
Crouch RB, Foley PA, and Baker CS
- Subjects
- Allergens pharmacology, Ambulatory Care Facilities, Australia epidemiology, Female, Humans, Incidence, Male, Mass Screening methods, Patch Tests, Photosensitivity Disorders epidemiology, Sensitivity and Specificity, Photosensitivity Disorders diagnosis, Sunscreening Agents pharmacology
- Published
- 2002
- Full Text
- View/download PDF
38. Dermatology.
- Author
-
Marks R, Foley PA, and Sinclair RD
- Subjects
- Australia, Dermatology trends
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.